BenevolentAI and AstraZeneca Collaborate on New Lupus Target
TL;DR
Adding a novel lupus target enhances AstraZeneca's portfolio, giving them an edge in the competitive pharmaceutical industry.
The collaboration between BenevolentAI and AstraZeneca focuses on data-driven approach to identify and validate new therapeutic targets for lupus.
Identifying new therapeutic targets for lupus can lead to improved treatments, offering hope to those suffering from this debilitating autoimmune disease.
Lupus is a complex autoimmune disease that causes chronic fatigue and organ damage, but new collaborative efforts offer potential breakthroughs in treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
BenevolentAI and AstraZeneca have announced a significant expansion of their ongoing collaboration with the addition of a new target for systemic lupus erythematosus (SLE) to AstraZeneca's discovery portfolio. This collaboration, which began in 2019, initially focused on idiopathic pulmonary fibrosis and chronic kidney disease, and later expanded to include heart failure and lupus.
Dr. Anne Phelan, BenevolentAI's Chief Scientific Officer, emphasized the importance of this partnership, stating, "We can really leverage the power of the interconnectivity of the data foundations to pull through potential target hypotheses irrespective of the disease." Phelan highlighted how BenevolentAI's data-driven approach, combined with AstraZeneca's disease expertise, facilitates the identification and validation of new therapeutic targets.
Lupus, described by Phelan as a debilitating autoimmune disease, causes the body's immune system to attack its own tissues, leading to chronic fatigue and damage to vital organs. The complex nature of lupus makes it a challenging disease to treat, underscoring the importance of innovative approaches in drug discovery.
The collaboration leverages BenevolentAI's platform, which is adept at handling complex data and generating explainable hypotheses. This capability is crucial in identifying new therapeutic targets for diseases like lupus, where traditional methods may fall short.
By combining their strengths, BenevolentAI and AstraZeneca aim to accelerate the discovery of new treatments for lupus, potentially bringing relief to millions of patients suffering from this chronic condition. The extension of their partnership signifies a promising step forward in the fight against autoimmune diseases.
For more information, visit the source version on newsdirect.com.
Curated from News Direct
